Follow Astrana Health to never miss an important update.
Astrana reported a strong third quarter with earnings per share of $0.71, which was well ahead of the $0.46 analysts expected. Revenue hit a record $1.02 billion, up 7 percent from last year. The company is seeing a massive jump in net income, which reached $20.3 million this quarter compared to just $1.1 million a year ago.
The results show that Astrana is getting better at managing medical costs through its technology platform. By taking on full responsibility for patient outcomes, the company earns more when it keeps patients healthy and avoids expensive hospital stays. This model is clearly scaling well, as the company also generated over $100 million in cash from its operations so far this year.
See the full quarter, and how our tracked metrics did
Source: 8-K filing
The benchmark Treasury yield, which sets the tone for interest rates across the economy, rose above 5.1 percent on Wednesday. This was the largest one-day increase in over a year.
For a company like Astrana, higher yields can be a double-edged sword. While they often signal a strong economy, they also make it more expensive for companies to borrow money for expansions or acquisitions. Additionally, when yields on safe government bonds rise, investors often sell riskier stocks, which contributed to the market's drop today.
Source: WSJ
Pomerantz LLP and Lowey Dannenberg are looking into potential claims on behalf of shareholders regarding possible violations of federal securities laws. These types of investigations are common after a stock price drop or when questions arise about a company's financial disclosures. While they often do not lead to significant legal trouble, they can create a distraction for management and a cloud of uncertainty for the stock until the matters are resolved.
Source: GlobeNewsWire
Oppenheimer set its price target for Astrana at $53 per share. This is very close to the average target of $52 across all Wall Street firms that follow the company. Since the stock is currently trading around $34, analysts generally believe the business is worth significantly more than its current market price, though a price target is just an estimate and not a guarantee of where the stock will go.
Source: Oppenheimer
After a string of misses in 2025, management has delivered three straight quarters of growing profit beats. This shift suggests the company has moved past its integration hurdles and is now consistently outrunning its own forecasts.
| Expectation | |
|---|---|
| EPS | $0.46 |
| Revenue | $1.02B |
Follow Astrana Health to get the latest and most important updates.
Follow ASTH